China blueprints drug-safety improvements

Chinese officials rolled out a plan to improve drug standards and monitoring over the next 5 years, saying "[m]edicinal safety is in a high-risk stage." Among the goals are stepped-up monitoring of adverse events, a credit-rating system, post-marketing surveillance and severe punishments for counterfeiters and misbehaving drug executives. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.